<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04915365</url>
  </required_header>
  <id_info>
    <org_study_id>01-2021-SU-HAECHO</org_study_id>
    <nct_id>NCT04915365</nct_id>
  </id_info>
  <brief_title>Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude</brief_title>
  <official_title>Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With Chronic Obstructive Pulmunary Disease (COPD) Traveling to High Altitude</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center of Cardiology and Internal Medicine, Kyrgyz Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, placebo-controlled double-blind trial is to evaluate the&#xD;
      effect of acetazolamide on right heart function at rest in lowlanders with chronic&#xD;
      obstructive pulmonary disease (COPD) traveling to high altitude (HA) and developing early&#xD;
      signs of altitude-illness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized placebo-controlled, double-blind, parallel-design trial will evaluate effect&#xD;
      of acetazolamide on right heart function in lowlanders with chronic obstructive pulmonary&#xD;
      disease (COPD) travelling to high altitude and developping early symptoms and/or signs of&#xD;
      impending altitude-illness. Qualifying participants will be randomized 1:1 to acetazolamide&#xD;
      or placebo treatment during their further stay of 2 days at 3'100 m.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, placebo-controlled, double-blind</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) An independent pharmacist will prepare identically looking active and placebo capsules labelled with secret codes. Codes will be concealed to investigators and patients until completion of data analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in change of pulmonary artery pressure</measure>
    <time_frame>3 days</time_frame>
    <description>Difference in change of pulmonary artery pressure (RV/RA) evaluated by echocardiography at 3100 m in the acetazolamide compared to the placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in change of pulmonary artery pressure (RV/RA) low altitude versus high altitude</measure>
    <time_frame>3 days</time_frame>
    <description>Difference in change of pulmonary artery pressure evaluated by echocardiography from 760 m baseline measurement to measurement at 3100 m in the acetazolamide compared to the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in cardiac output</measure>
    <time_frame>3 days</time_frame>
    <description>Difference in change of cardiac output evaluated by echocardiography in the acetazolamide compared to the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in right heart dimensions</measure>
    <time_frame>3 days</time_frame>
    <description>Difference in change of right heart dimensions evaluated by echocardiography in the acetazolamide compared to the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in right heart function</measure>
    <time_frame>3 days</time_frame>
    <description>Difference in change of tricuspid annular plane systolic sxcursion (TAPSE) evaluated by echocardiography in the acetazolamide compared to the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in right heart function</measure>
    <time_frame>3 days</time_frame>
    <description>Difference in change of fraction area change (FAC) evaluated by echocardiography in the acetazolamide compared to the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in right heart function</measure>
    <time_frame>3 days</time_frame>
    <description>Difference in change of tissue dopple S (TDI S) evaluated by echocardiography in the acetazolamide compared to the placebo group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Right Heart Function</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Altitude Sickness</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses&#xD;
1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>Acetazolamide, oral capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses&#xD;
1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo, oral capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, age 35-75 y, living at low altitude (&lt;800 m).&#xD;
&#xD;
          -  COPD diagnosed according to the Global Initiative for Obstructive Lung Disease (GOLD)&#xD;
             guidelines, FEV1 40-80% predicted, pulse oximetry&#xD;
&#xD;
             ≥92%, PaCO2 &lt;6 kPa, breathing ambient air at 760 m.&#xD;
&#xD;
          -  One of the following early signs and/or symptoms of impending altitudeillness&#xD;
             identified by self-monitoring during ascent to or stay at 3100 m:&#xD;
&#xD;
          -  Pulse oximetry SpO2≤84%&#xD;
&#xD;
          -  Headache or nausea/vomiting or fatigue/weakness or dizziness/lightheadedness of at&#xD;
             least moderate intensity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COPD exacerbation, very severe COPD with hypoxemia or hypercapnia at 760 m (see&#xD;
             above).&#xD;
&#xD;
          -  Other lung disease, relevant comorbidities (such as uncontrolled cardiovascular&#xD;
             disease, i.e., unstable arterial hypertension, coronary artery disease; previous&#xD;
             stroke; obesity (body mass index &gt;35 kg/m2); internal, neurologic, rheumatologic or&#xD;
             psychiatric disease; current heavy smoking (&gt;20 cigarettes per day).&#xD;
&#xD;
          -  Renal failure and/or allergy to sulfonamides.&#xD;
&#xD;
          -  Patients who do not have early signs and/or signs of impending altitudeillness by&#xD;
             self-monitoring (as defined above) at 3'100m will not be included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Ulrich, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Zürich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Talant M Sooronbaev, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Ulrich, Prof</last_name>
    <phone>+41442552220</phone>
    <email>silvia.ulrich@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Konrad E. Bloch, Prof</last_name>
    <phone>+41442553828</phone>
    <email>konrad.bloch@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center of Cardiology and Internal Medicine</name>
      <address>
        <city>Bishkek</city>
        <zip>720040</zip>
        <country>Kyrgyzstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talant M Sooronbaev, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Kyrgyzstan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>May 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetazolamide</keyword>
  <keyword>Mountain sickness</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Altitude Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

